COVID-19 and Thrombosis: From Bench to Bedside

Link to article at PubMed

Trends Cardiovasc Med. 2020 Dec 15:S1050-1738(20)30157-2. doi: 10.1016/j.tcm.2020.12.004. Online ahead of print.


Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link between COVID-19 and thrombosis is attracting attention from the broad scientific community. In this review we will analyze the current available knowledge of the association between COVID-19 and thrombosis. We will highlight mechanisms at both molecular and cellular levels that may explain this association. In addition, the article will review the antithrombotic properties of agents currently utilized or being studied in COVID-19 management. Finally, we will discuss current professional association guidance on prevention and treatment of thromboembolism associated with COVID-19.

PMID:33338635 | DOI:10.1016/j.tcm.2020.12.004

Leave a Reply

Your email address will not be published. Required fields are marked *